Dynavax Technologies brings Sanofi a commercialized hepatitis B vaccine and a clinical-stage shingles vaccine, both of which offer differentiation from products marketed by GSK. It’s Sanofi’s second billion-dollar vaccines acquisition of 2025.
The post Sanofi’s Vaccine Lineup Gets a Shot in the Arm With $2.2B Dynavax Acquisition appeared first on MedCity News.
